SLC5A2 and heart failure: The EMPA-REG OUTCOME, the CANVAS and the DECLARE-TIMI58 trials showed that SGLT2 inhibitors reduced the risk of cardiovascular death or hospitalization for heart failure in T2D individuals with established CVD [18–20].